REGN - Spark Newswire

3 minute read

FDA
News

Regeneron Pharmaceuticals Says FDA Expands Authorized Use Of REG-COV

July 30, 1:45 PM

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) updated the Emergency Use Authorization (EUA) for the investigational COVID-19 antibody cocktail

REGN

1 minute read

Regeneron – Sanofi’s Dupixent Improves Itch, Hives In Inflammatory Skin Disease Patients

By Vandana Singh

July 29, 7:06 AM

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) have

REGN

4 minute read

FDA
News

Regeneron Announced Japan Approved Antibody Cocktail (casirivimab and imdevimab) for the Treatment of Mild to Moderate COVID-19

By Charles Gross

July 20, 5:57 AM

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Regeneron's casirivimab and imdevimab antibody cocktail to treat patients with mild to moderate COVID-19. This marks the first time the antibody cocktail, known as REGEN-COVTM in the U.S.

REGN

1 minute read

Governor Cuomo Backs Regeneron’s $1.8B Expansion Plans In Westchester County

By Vandana Singh

July 16, 12:32 PM

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) plans to spend $1.8 billion and hire 1,000 new workers as part of an ambitious, two-phase expansion…

REGN

1 minute read

AMD And Biogen Lead The QQQ Lower Thursday

By Henry Khederian

July 15, 4:12 PM

U.S. indices were trading lower Thursday as investors weigh Fed Chair Powell’s comments on inflation to the Senate banking panel.

AMC

1 minute read

Benchmark Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $636

By Benzinga Newsdesk

July 8, 8:45 AM

Benchmark analyst Aydin Huseynov maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $590 to $636.

REGN

2 minute read

Silverback Therapeutics Announces Clinical Supply Agreement with Regeneron to Evaluate SBT6050 in Combination with Libtayo, Initially in HER2-expressing Non-Small Cell Lung and Gastric Cancers

By Benzinga Newsdesk

July 7, 7:32 AM

Silverback Therapeutics, Inc. (NASDAQ:SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue

REGN

2 minute read

Regeneron Discovers GPR75 Gene Mutations Can Protect Against Obesity, Begins Search For New Drugs

By Vandana Singh

July 2, 7:57 AM

A team at Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) Genetics Center has discovered mutations in the gene GPR75 that protect against obesity. Now,…

REGN

1 minute read

Facebook And Nvidia Lead The QQQ Thursday

By Henry Khederian

July 1, 4:09 PM

U.S. indices are trading higher following better-than-expected jobless claims, which lifted recovery sentiment to start off July.

AMZN

3 minute read

News

Regeneron Genetics Center Discovers GPR75 Gene Mutations that Protect Against Obesity

By Michael Horton

July 1, 2:06 PM

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that scientists from the Regeneron Genetics Center® (RGC) have discovered rare genetic mutations in the GPR75 gene associated with

REGN

Feed Symbols: REGN